Novo Nordisk(US:NVO) 阿尔法工场研究院·2025-10-23 00:08Core Viewpoint - Novo Nordisk is undergoing significant leadership changes, with a total of seven executives, including Chairman Helge Lund, set to leave after a temporary shareholders' meeting on November 14. This shake-up is primarily due to disagreements between the board and the controlling shareholder, the Novo Nordisk Foundation, regarding the future composition of the board [4][5][6]. Leadership Changes - The board's proposal for a restructuring aimed at adding new members while maintaining continuity was not accepted by the Novo Nordisk Foundation, which preferred a broader overhaul [4][5]. - The new proposed chairman, Lars Rebien Sørensen, will have a term of 2-3 years, focusing on supporting the new management's transformation plan and identifying a successor to lead the company into the 2030s [7][9]. - Sørensen has been involved with the board since May 16, when the previous CEO, Lars Fruergaard Jørgensen, resigned, leading to a series of executive changes [10]. Strategic Focus - The new CEO, Maziar Mike Doustdar, aims to consolidate Novo Nordisk's leadership in obesity and diabetes treatment through innovation and a performance-driven culture [10][11]. - Doustdar's strategic priorities include optimizing the cost structure and enhancing efficiency while making strategic investments in key areas [10][11]. Market Competition - Novo Nordisk faces intensified competition in the GLP-1 market, particularly from Eli Lilly, which has seen significant sales growth in its competing products [13][14]. - The company is also dealing with external pressures, including potential price reductions for its diabetes drug Ozempic, which could impact revenue [14][16]. - Novo Nordisk's sales figures for Ozempic reached 112.76 billion Danish Krone (approximately 16.63 billion USD) in the first half of the year, while Eli Lilly's products showed strong growth, narrowing the sales gap [16][17]. Financial Outlook - Despite strong sales, Novo Nordisk has lowered its profit expectations for 2025, reflecting a more competitive market and slower-than-expected growth in GLP-1 drug usage [17]. - The company continues to pursue market expansion for its weight loss version of semaglutide and is investing in commercial activities to enhance market penetration [17].